1.Litwic, A., et al., Epidemiology and burden of osteoarthritis. Br Med Bull, 2013. 105: p. 185–99.
2.Guidelines for the diagnosis and treatment of Osteoarthritis (2007 edition) %J Chinese Medical Journal. 2008(01): p. 28–30.
3.Antman, E. M., et al., Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation, 2007. 115(12): p. 1634–42.
4.Silverstein, F. E., et al., Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000. 284(10): p. 1247–55.
5.Whelton, A., Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med, 1999. 106(5B): p. 13S–24S.
6.Wolfe, M. M., D. R. Lichtenstein, and G. Singh, Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med, 1999. 340(24): p. 1888–99.
7.Zhang, W., et al., OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage, 2010. 18(4): p. 476–99.
8.Bookman, A. A., K. S. Williams, and J. Z. Shainhouse, Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ, 2004. 171(4): p. 333–8.
9.Conaghan, P. G., et al., A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA–033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. Rheumatology (Oxford), 2013. 52(7): p. 1303–12.
10.Komatsu, T. and T. Sakurada, Comparison of the efficacy and skin permeability of topical NSAID preparations used in Europe. Eur J Pharm Sci, 2012. 47(5): p. 890–5.
11.van Haselen, R. A. and P. A. Fisher, A randomized controlled trial comparing topical piroxicam gel with a homeopathic gel in osteoarthritis of the knee. Rheumatology (Oxford), 2000. 39(7): p. 714–9.
12.Cheng, C. W., et al., Extending the CONSORT Statement to moxibustion. J Integr Med, 2013. 11(1): p. 54–63.
13.Huang, Q., et al., Bibliometric Analysis of Diseases Spectrum of Moxibustion Therapy %J Journal of Acupuncture and Tuina Science. 2012. 10(06): p. 342–348.
14.Zhao, L., et al., Effectiveness of moxibustion treatment as adjunctive therapy in osteoarthritis of the knee: a randomized, double-blinded, placebo-controlled clinical trial. Arthritis Res Ther, 2014. 16(3): p. R133.
15.Ren, X., et al., Effectiveness of moxibustion treatment in quality of life in patients with knee osteoarthritis: a randomized, double-blinded, placebo-controlled trial. Evid Based Complement Alternat Med, 2015. 2015: p. 569523.
16.Li, C., Y. Han, and B. Dong, Effect of acupuncture moxibustion on RANTES and MCP–1 expression of knee osteoarthritis %J Journal of Liaoning University of Traditional Chinese Medicine. 2013. 15(10): p. 79–81.
17.Xiong, Y., R. Peng, and S. Xia, Expression of interleukin 1β and tumor necrosis factor alpha in articular fluid of knee osteoarthritis in rabbits and its effect on moxibustion %J Chinese Organization Engineering Research. 2010. 14(41): p. 7700–7703.
18.Tan, C., et al., Preliminary correlation between warm needling treatment for knee osteoarthritis of deficiency-cold syndrome and metabolic functional genes and pathways. J Acupunct Meridian Stud, 2010. 3(3): p. 173–80.
19.Zhou, Z., et al., Therapeutic effect of separating moxibustion on blood stasis type knee osteoarthritis %J Shanghai Journal of Acupuncture and Moxibustion. 2010. 29(01): p. 45–47.
20.Sun, K., J. Yang, and D. K. Shen, [Clinical observation on treatment of primary knee osteoarthritis of liver and kidney deficiency type with Aconite cake-separated moxibustion]. Zhongguo Zhen Jiu, 2008. 28(2): p. 87–90.
21.Kim, T. H., et al., Moxibustion treatment for knee osteoarthritis: a multi-centre, non-blinded, randomised controlled trial on the effectiveness and safety of the moxibustion treatment versus usual care in knee osteoarthritis patients. PLoS One, 2014. 9(7): p. e101973.
22.Song, G. M., et al., Moxibustion is an Alternative in Treating Knee Osteoarthritis: The Evidence From Systematic Review and Meta-Analysis. Medicine (Baltimore), 2016. 95(6): p. e2790.
23.Choi, T. Y., et al., Moxibustion for the treatment of osteoarthritis: An updated systematic review and meta-analysis. Maturitas, 2017. 100: p. 33–48.
24.MacPherson, H., et al., Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): Extending the CONSORT statement. J Evid Based Med, 2010. 3(3): p. 140–55.
25.Zhou, J. Y., et al., Moxibustion versus diclofenac sodium gel for the treatment of knee osteoarthritis: a study protocol for a double-blinded, double-placebo, randomised controlled trial. BMJ Open, 2017. 7(4): p. e012879.
26.Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum, 2000. 43(9): p. 1905–15.
27.Chen, N., et al., Study on the law of Acupuncture and moxibustion treatment of KOA using the data mining %J Chinese Journal of TCM Information. 2016. 23(03): p. 31–34.
28.Yang, H., S. Chen, and J. Li, Study on acupuncture and moxibustion treatment of knee joint osteoarthritis with data mining %J Chinese Journal of TCM Information. 2017. 24(01): p. 95–98.
29.Zhao, B., et al., A novel sham moxibustion device: a randomized, placebo-controlled trial. Complement Ther Med, 2006. 14(1): p. 53–60; discussion 61.
30.Bellamy, N., et al., Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol, 1988. 15(12): p. 1833–40.
31.Altman, R., et al., Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum, 1986. 29(8): p. 1039–49.
32.in Osteoarthritis: Care and Management in Adults. 2014: London.
33.Dawson, J., et al., Impact of persistent hip or knee pain on overall health status in elderly people: a longitudinal population study. Arthritis Rheum, 2005. 53(3): p. 368–74.
34.Marusic, A. and S. F. Ferencic, Adoption of the double dummy trial design to reduce observer bias in testing treatments. J R Soc Med, 2013. 106(5): p. 196–8.
35.Wang, L. P., et al., Efficacy of acupuncture for migraine prophylaxis: a single-blinded, double-dummy, randomized controlled trial. Pain, 2011. 152(8): p. 1864–71.
36.Baraf, H. S., et al., Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial. Phys Sportsmed, 2010. 38(2): p. 19–28.
37.Stockfleth, E., et al., Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0.015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp. Br J Dermatol, 2018. 178(2): p. 433–442.
38.Moreira, S. A. and D. J. Liu, Diclofenac systemic bioavailability of a topical 1% diclofenac + 3% menthol combination gel vs. an oral diclofenac tablet in healthy volunteers: a randomized, open-label, crossover study. Int J Clin Pharmacol Ther, 2017. 55(4): p. 368–372.
39.Wadsworth, L. T., J. D. Kent, and R. J. Holt, Efficacy and safety of diclofenac sodium 2% topical solution for osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled, 4 week study. Curr Med Res Opin, 2016. 32(2): p. 241–50.
40.Nelson, C., et al., Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol, 2004. 3(4): p. 401–7.